Evopoint prices Shanghai IPO to raise about $270M

What's the deal? Suzhou SinoV Pharmaceutical TechnologyDealroom has a profile for this one. Try Dealroom →, which operates as Evopoint Biosciences, has priced its Shanghai initial public offering to raise 1.8 billion yuan, or roughly $270 million. The listing was announced in September 2026.

Why now? The IPO gives the biopharmaceutical company access to public capital markets in China, a step that typically funds drug development and expansion.

The signal: Evopoint's move adds to activity in China's biotech listings, where domestic exchanges remain a key funding route for drug developers seeking to scale.

Image credit: foteih